Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2016 3,25 M
EBIT 2016 -23,8 M
Net income 2016 -23,5 M
Debt 2016 4,25 M
Yield 2016 -
Sales 2017 5,85 M
EBIT 2017 -21,8 M
Net income 2017 -21,7 M
Debt 2017 11,0 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 40,7x
EV / Sales2017 23,8x
Capitalization 128 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
09/21Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
07/07 ONXEO COLLABORATES WITH THE ROYAL CO : Onxeo samarbejder med Royal College of Su..
07/05 ONXEO : Receives USPTO Notice of Allowance for Key AsiDNATM Patent, Extending IP..
07/04 ONXEO RECEIVES USPTO NOTICE OF ALLOW : Onxeo modtager “Notice of Allowance..
06/27 ONXEO ADVANCES DEVELOPMENT PLAN FOR : Onxeo offentliggør udviklingsplan for det..
06/27 ONXEO : advances development plan for first-in-class signal interfering DNA comp..
06/03 ONXEO : Announces Development of Beleodaq Oral Formulation Opening New Opportuni..
06/02 ONXEO ANNOUNCES DEVELOPMENT OF BELEO : Onxeo offentliggør udviklingen af en oral..
05/02 PUBLICATION OF 2015 REFERENCE DOCUME : Offentliggørelse af Reference Document fo..
04/28 ONXEO : First Quarter 2016 Financial information and Business Update
04/06 ONXEO : Passing on Onxeo’s Extraordinary and Ordinary General Meeting // D..
More news
Sector news : Pharmaceuticals - NEC
02:55aDJWALGREENS BOOTS ALLIANCE : Theranos Walks Away From Zika Test
01:33a ASTRAZENECA : to pay $5.52 million to resolve U.S. SEC foreign bribery case
08/30 U.S. slams EU, but Apple tax demand first issued in Washington
08/30DJFDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30DJNOVARTIS : FDA Approves Novartis's Biosimilar to Amgen's Enbrel
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 9,00 €
Spread / Average Target 191%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Graham K. Dixon Chief Scientific Officer
David Horn Solomon Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA143
JOHNSON & JOHNSON16.31%326 855
ROCHE HOLDING LTD.-12.84%214 220
PFIZER INC.8.05%211 570
NOVARTIS AG-10.83%209 772
ASTRAZENECA PLC7.33%174 031
More Results